Free Essays on A Dolls House: Marital Lessons :: Dolls House essays

Marital Lessons from A Doll's House    Divorce has become widely accepted throughout the world. In today's world, the violent shredding of a family is shrugged off like the daily weather.   The Norwegian play A Doll's House, by Henrik Ibsen, is a prime example of a marriage that didn't work. The marriage of Torvald and Nora Helmer had many problems because the husband and wife couldn't discover the secrets of marital bliss. To keep a marriage alive and growing it must hold true to four qualities: love, communication, trust and loyalty, and perseverance. With the incorporation of these qualities any marriage would work.    Without love a relationship would probably not even begin. Two people meet, a friendship forms, and soon a romance blossoms. Though the basis for Nora and Torvald's relationship appeared to be centered around love, the needed balance was not obtained. Torvald didn't really love Nora; to him she was just another child to mind. He said, 'And I wouldn't want you to be any different from what you are-just my sweet little song bird. But now I come to think of it, you look rather-rather-how shall I put it? -rather as if you've been up to mischief today' ( 151). Calling his wife names such as 'skylark,' 'squirrel,' and 'spendthrift,' Torvald does not love his wife with the respect and sensitivity a man should. The main area where Torvald showed his lack of love for Nora was in the way he managed his house. Torvald was the owner of what he believed to be a perfect doll house. This doll house was first controlled by Nora's domineering father, and once Nora entered marriage, the titles and dee ds to this doll house were handed over to Torvald. Torvald manipulated Nora, and then the children through her according to his wants, sure that he could never lose control over his precious doll house. This lack of love and imperious attitude would eventually ruin their marriage. Nora was the only one of the two partners who showed love for the other in this play. Going against all the odds a woman faced in the late nineteenth century, Nora went behind her husband's back, borrowed a large sum of money, forged her father's signature, and went on to pay it off with hopes of Torvald never hearing of it. She refused to be a doll, and would alternate personalities between 'Torvald's little skylark,' and 'Nora the intelligent and strong woman.

The Second World War (WWII) - Causes And Effects Essay -- World War 2

World War II: Causes, and Affects In the history of the world there are many occurrences that have changed life and the world, as we know it. The history of conflicts in the world is just as long as the histories of man have bee recorded. From the beginning the human species survived off of conflict (between various predators and the environment) and has been nourished by the fruits of war since before the rise of the Roman Empire. World conquest has been the goal of many great generals and a great many Kings. Through the years there were many conflicts that were thought to be the worst that ever was and the worst that would ever be (World War I in particular). World war two is said to be the war to end all wars, because of the leaders, the technology, and the effects the war had on the world. World War II began in 1939. The devastation and destruction caused in this conflict will have a total global effect. The war itself will require many countries to commit all of their military and financial assets in the production of war equipment and in fighting. This was the first war that had civilian death rates that exceeded all previously set records, and from any war since. The battlefield in world war two included all of the territory in the country. The days of strictly trench and open field battles were a thing of the past. The location of battles and bombings included strictly military sites and also various other locations that were essential to the life and economy of the country involved. The reason this war was different from al of the other wars of the past was that the weaponry has changed from the conventional to the extraordinary. The causes of World War II are linked closely to the end of World War I. The trouble began when the Treaty of Versailles was written. The Treaty of Versailles was written by the powers that won World War I (Britain, France, and US). They divided Europe up as they saw fit and reduced the territory held by Germany to less than before its series of conquests. The Germans lost all of their colonies and one eighth of its land in Europe (Encarta 98). Italy profited from the war, Italy gained land and power (but still wanted more). The French wanted to make Germany pay the maximum penalty for its four-year occupation of France that began in 1914(Strauss 14). The German Government was given orders to pay restitution to the countr... ...tomic weapon is detonated in a city.   Ã‚  Ã‚  Ã‚  Ã‚  World war two is said to be the war to end all wars, because of the leaders, the technology, and the effects the war had on the world. World War II cost the world more lives, and property than any other war before. It was the testing ground for weapons of such horrible destructive power that if they were ever to be used again it would probably be the end of the world. The war involved sixty-one countries, 1.7 billion people, 110 million military personnel, left over 60 million dead, 35 million of the dead were civilian casualties, and the war cost over 1 trillion dollars. If a war ever occurs that could possible top all of those statistics and numbers it would most likely be the end of civilization, as we know it and of life on this earth as we know it. Works Cited Grolier’s Electronic Encyclopedia. CD-ROM. New York: 1994 Microsoft Encarta 98 Encyclopedia. CD-ROM. New York: Microsoft,1998  Ã‚  Ã‚  Ã‚  Ã‚   â€Å"World War II†. World Book Encyclopedia. 1996 ed. Strauss, Martin L. Gestapo:Stories of Terror. New York: Free, 1992. Johnson, Michelle F. The Cost of Liberty. Philadelphia: Associated Press, 1935.

Nicolò Paganini

When Paganini walked along the street, people eyed him closely, wondering whether they might detect his cloven foot-a mark of the devil. Once, shortly before he was to go onstage, he felt a nail in his shoe, which caused him to limp slightly as he arrived on the podium. Some members of the audience looked at each other knowingly, for it was widely believed that there was something mysterious, supernatural about his playing. Even people who did not believe in the devil were convinced of it. Ever since they have tried to discover his secret. For almost a year, an Englishman followed him on his tours, taking an adjoining hotel room and listening constantly. While on the road, however, Paganini hardly ever practiced, and when he briefly warmed up before concerts, he used such a heavy mute that no one could hear him (Prod'Homme 13). Countless books and pamphlets have been written about the secret of his practicing and about other, hitherto unknown, explanations of his virtuosity. Much has been brought to light that is interesting and informative, but no secrets have been revealed. Paganini's accomplishments must be attributed to a handful of quite understandable factors, as is true of above-average achievement in any field. In his case we are aware of great musicality; a distinct talent for the violin that included certain physiological characteristics; a strict practicing regime supervised by his father, who soon noted the unusual gift; and a highly developed desire to excel as an artist. All produced astonishing results (Anders 39). Paganini was born in Genoa in 1782, the son of a dockworker whose hobbies included fortunetelling and playing the violin and mandolin. He taught Nicolà ² both instruments. â€Å"It would be hard to imagine a stricter father,† the boy recalled. Further instruction by two orchestra violinists led to lessons by Giacomo Costa, music director at the cathedral, whose pupil soon performed solos there. This was a customary eighteenth-century venue, as it had been for Tartini, and such appearances in church were occasionally reviewed in the press. On 31 May 1794 a notice was printed in Avvisi, a Genoa newspaper: â€Å"[During high mass] Nicolà ² Paganini, a highly gifted eleven-year-old boy, performed a concerto, for which he was greatly admired.† (Prod'Homme 7-8) Encouraged by such successes, the father entrusted the thirteen-yearold Nicolà ² to Alessandro Rolla, then teaching in Parma. Though Rolla declared that there was nothing he could teach him, he gave his young student a solid foundation in music theory, and probably good advice as well. While in Parma, Nicolà ² also studied counterpoint with Ghiretti and Paà «r, for whom he wrote, among other exercises, twenty-four fugues in parts. Years of intensive practice under the father's strict supervision followed his return home. During this period he acquired the phenomenal command of the violin that amazed musicians and music lovers everywhere (Anders 40-41). Paganini stands at the threshold of a new era in violin playing, if later in life he referred to himself as self-taught, this does not imply a lack of gratitude to his teachers. He developed his very individual style of playing on his own, during his up to twelve hours of daily practice, as he recalled. In 1801 he freed himself of his father's relentless supervision by joining the orchestra in Lucca as a first violinist. Five years later he moved on to the court of Napoleon's sister Elisa Bacciocchi, then princess of Lucca. He remained there until 1809, active as a soloist, music director, orchestra member, and chamber music player. His career as a touring virtuoso did not begin until 1813 when, thirty-one years old, he reaped such spectacular successes in Milan that the world took notice (Anders 42). Paganini was a compulsive gambler who at times came close to being sent to debtor's prison, and who once had to use his violin to pay his debts. In this dilemma, someone presented him with a Guarneri violin so that he could play a concert that had already been scheduled (McGinnis 117). The sensational aspects of Paganini's public appearances were heightened by a wealth of freely invented stories, such as the one about his prison sentence, for which there is absolutely no foundation. While he played the violin in prison, it is related, three strings broke, one after another, until only the G string remained, so that he was forced to develop his uncanny ability to play on one string alone (Athanassoglou-Kallmyer 1). The later â€Å"Moses† Fantasy is one of his compositions demonstrating this skill.) According to another wild story he strangled his wife (in fact, Paganini never married) and used her intestines as raw material for strings. Such stories may have been inspired by the virtuoso's fondness, reminiscent of Don Giovanni's, for the fair sex, which indeed accounted for many romantic adventures in his youth. Stories persisted, even late in his life, about wealthy countesses and others who offered him their money and their everything-stories that of course were good publicity. It is a fact that his profoundly melancholic appearance and his haggard, mephistophelian figure held a strong fascination for women, which he did not mind at all (Prod'Homme 24). Behind the virtuoso facade he cultivated, there was another Paganini-the one who in private gatherings played Beethoven quartets well and with great enthusiasm, including the late quartets. When on tour, he missed no opportunity to hear Fidelio or Don Giovanni. He also was quite fond of older vocal music, especially Palestrina's (Prod'Homme 24). Paganini's fame was restricted to Italy until 1828, when, at the age of forty-six, he traveled to Vienna for his first engagement abroad. The impression he made there defies imagination. The first recital took place on 29 March in the Redoutensaal, filled to capacity (Athanassoglou-Kallmyer 2). All local violinists were there, along with Schubert, the poet Grillparzer, the Esterhà ¡zy family, and everyone who was anyone in the arts and in society. Thirteen more concerts followed, all equally crowded. A veritable Paganini mania broke out (Prod'Homme 35). Strauss wrote a â€Å"Paganini Waltz,† merchants offered Paganini schnitzel, cravats, and haircuts. When Paganini's good business sense led him to raise the price of admission to one gold florin, that coin became known as a â€Å"Paganinerl.† There were poems of fulsome admiration, and the critics outdid each other writing hymns of praise. Until 1831, Paganini chiefly concertized in Germany, residing in Frankfurt on the Main. Some during this period refused to be caught up in the delirious adulation and were all the more critical of the violinist and his mesmerized public. Others were more insightful and understanding of the changing times (Athanassoglou-Kallmyer 1). Serious scholars, eccentrics, journalists, and charlatans ever since have tried to discover the miracle of his playing and its effect on audiences. Some significant details were established, but anyone who tried to build an entire system on such discoveries, even a philosophy of violin playing, lost their credibility. As Flesch (The Art of Violin Playing, vol. 2) said, â€Å"A publication whose title uses the name Paganini as a sales placard impresses one at once as a mere advertising puff† (Flesch 85). Paganini must be credited with inaugurating a new era, not only for violin playing but for instrumental accomplishment in general. The standards he set are still valid in our time. Liszt, a genius, was able by virtue of great effort and superhuman concentration, to adapt Paganini's technique to his own piano playing. It took violinists almost a century to accomplish this for their instrument and to develop pedagogical methods based on Paganini's achievements. Works Cited Anders, G. E. Nicolo Paganini: His life, personality, and secrets. Dover Publications, 1991. Athanassoglou-Kallmyer, Nina. â€Å"Blemished Physiologies: Delacroix, Paganini, and the    Cholera Epidemic of 1832†. The Art Bulletin, Vol. 83, 2001. Flesch, Carl. Art of Violin Playing: Book Two. Carl Fischer Music Dist, 2000. McGinnis Ferguson, Hugh. No Gambling at the casino Paganini. The Phi Beta Kappa Society   Ã‚   in The American Scholar, 1994. Prod'Homme, Jacques Gabriel. Nicolo Paganini. Ams Pr Inc, 1975.      

Mba Spring2011 Merck Sample Group Project

DELAWARE STATE UNIVERSITY (MBA – Spring 2011) Strategic Management Case Study Executive Summary:3 Current Vision4 Current Mission4 Values5 Current Strategies:6 Developed Vision7 Developed Mission7 Reason for new mission8 SWOT Analysis9 External opportunities:9 External Threats:10 Financial and Operating Performance Analysis11 Close Competitors11 Ratio Analysis11 Key Industry Ratios14 Operating Profit margin14 Net Profit margin14 Current Ratio14 Return on Assets15 Debt/Equity Ratio15 Inventory Turnover Ratio15 Revenue Growth16 Market Share16 Internal Strengths16Internal Weakness20 External Factor Evaluation Matrix21 Competitive Profile Matrix23 Internal Factor Evaluation24 Space Matrix27 SWOT Matrix29 Grand Strategy Matrix31 Recommended Strategies31 Recommended strategy No. 1:31 Recommended strategy No. 2:32 Projected Financial Statements33 Projected Ratios34 Company worth Analysis34 Annual Objectives:35 Strategic Review and Evaluation Procedures:35 Bibliography:36 Executive Su mmary: Merck & Co. is a research driven pharmaceutical company involved in manufacturing of pharmaceuticals and drugs.Merck's products are not limited to preventive and therapeutic vaccines. Merck merged with Schering-Plough in November of 2009 for $41billion. Merck is based in Whitehouse Station, New Jersey and has more than 110000 employees. The company has a annual revenue of $45billion during the year ending December 2010. The increase in revenues was mainly due to the incremental sales resulting from the inclusion of the post-merger results of Schering-Plough products. The operating profit of the company was $1,653. 0 million during FY2010, a decrease of 90% over 2009.The net profit was $859 million in FY2010, an increase of 93% over 2009. Merck’s products include preventive and therapeutic vaccines sold by prescription to treat human disorders and to also treat animal health. The company manages many products in different segments. Human health pharmaceutical produc ts consist of prescription therapeutic and preventive agents for the treatment of human disorders. Merck distributes its human health pharmaceutical products to retailers, government, drug companies, health and wellness organizations, and others.Merck's vaccine products are primarily managed and administered at physician offices. These products include preventive vaccines. The US Centers for Disease Control and Prevention Vaccines for Children program is a major customer for some of these vaccines. Merck also manages a clinical pipeline that has products in many different disease domains not limited to diabetes, heart strokes, hyper-tension, inflammatory problems, neurology related diseases, osteoporosis, respiratory, female health and many other prominent and new domains.This pipeline is managed in phases followed by a few ready for registration. Majority of these are subject to FDA approval before commercial manufacturing commences. Merck also manages vaccines for animal health an d this is a growing segment where there is more need for research for prevention of many diseases in animals. In addition to the above many different segments, Merck also manages a portfolio of regular consumer healthcare and manufactures many OTC products, foot and sun care products not just in the USA but also in Canada. Current VisionWe make a difference in the lives of people globally through our innovative medicines, vaccines, and consumer health and animal products. We aspire to be the best healthcare company in the world and are dedicated to providing leading innovations and solutions for tomorrow. (1) Current Mission To provide innovative, distinctive products and services that save and improve lives and satisfy customer needs, to be recognized as a great place to work, and to provide investors with a superior rate of return. (1) | Mission Component| Accomplished? | 1| Customers| No| | Products or Services| Yes| 3| Markets| No| 4| Technology| No| 5| Concern for survival, gro wth and profitability| No| 6| Philosophy| No| 7| Self-Concept| No| 8| Concern for public image| Yes| 9| Concern for employees| Yes| Values Our business is preserving and improving human life. We also work to improve animal health. All of our actions must be measured by our success in achieving these goals. We value, above all, our ability to serve everyone who can benefit from the appropriate use of our products and services, thereby providing lasting consumer satisfaction.We are committed to the highest standards of ethics and integrity. We are responsible to our customers, to Merck employees and their families, to the environments we inhabit, and to the societies we serve worldwide. In discharging our responsibilities, we do not take professional or ethical shortcuts. We are dedicated to the highest level of scientific excellence and commit our research to improving human and animal health and the quality of life. We strive to identify the most critical needs of consumers and cust omers, and we devote our resources to meeting those needs.We expect profits, but only from work that satisfies customer needs and benefits humanity. This depends on maintaining a financial position that invites investment in leading-edge research and that makes it possible to effectively deliver the results of that research. Our ability to excel depends on the integrity, knowledge, imagination, skill, diversity and teamwork of our employees. To this end, we strive to create an environment of mutual respect, encouragement and teamwork. We also strive to reward commitment and performance and be responsive to the needs of our employees and their families. 1) Current Strategies: * The Access Strategy aims at increasing access to medicines, vaccines, and healthcare in the emerging and developed countries. * To ensure safety and quality of products, Merck introduced a ‘Anti-counterfeiting’ strategy to prevent counterfeits across the world. Merck has setup an advanced laborato ry to implement this strategy.* To restore confidence as a quality producer of global vaccines, Merck continues to implement vaccine supply manufacturing strategy. * Merck continues to implement its global diversity strategy. * Merck’s research strategy is designed to mprove productivity and the probability of success and this is monitored by a Research Strategy Review Committee. * The most popular MRL strategy i. e. Merck Research Laboratory strategy is designed to manage the pipeline that uses the expertise to treat many unsolved diseases and health issues. MRL scientists are passionate about resolving and meeting unmet medical needs. * Merck established External Basic Research (EBR) and an EBR strategy are formulated to expand the scope and size of Merck’s early pipeline through partnerships with external partners. * Merck follows a responsible pricing policy thru its worldwide tiered pricing strategy. To foster health literacy in Switzerland, Merck follows the Swis s e-health strategy and as part of this strategy, they work with universities around the world. * Merck formed a Global Labor Relations Strategy to include global labor guidelines and principles and monitoring tools worldwide.* Merck energy management strategy serves as a useful framework in measuring current performance resulting in Merck receiving the Energy Star sustained excellence award. * Merck’s corporate strategy is â€Å"Plan to win†. * Merck has a supply strategy that combines the skills of internal and external manufacturers. (1) Developed Vision Our vision is to be an outstanding and most trusted company in the world’s healthcare and pharmaceutical industry. † Developed Mission We are passionately committed to providing creative, comprehensive and effective health solutions (2) that will improve the health, wellness and quality of life of our customers (1), consumers and partners around the globe for today, tomorrow and forever thru our continu ed superior performance, intelligent and creative employees (9), innovative and qualitative safe products, sustainable and profitable partnerships and by building increased shareholder returns thru this process.We will focus on increasing healthcare access (6) in the local and emerging markets (3) and will strive to use modern environment friendly technology(4) for our scientific innovation to improve productivity and to reduce costs to make our products more affordable. We will serve the society and the eligible people (8) with programs that will provide free and cost effective health solutions. We will collaborate with global research companies to lead and contribute to the resolution of global health issues (7) and we will position ourselves as the best in the industry with sustainable prosperity(5). Mission Component| Accomplished ? | 1| Customers| Yes| 2| Products or Services| Yes| 3| Markets| Yes| 4| Technology| Yes| 5| Concern for survival, growth and profitability| Yes| 6| P hilosophy| Yes| 7| Self-Concept| Yes| 8| Concern for public image| Yes| 9| Concern for employees| Yes| Reason for new mission The current mission is not exciting and does not emphasize on all the key components of an effective mission. The new mission emphasizes on health solutions as a whole versus products and services only. The new mission is targeted towards the wellbeing of the end consumer and not just to save the life.The focus is specifically mentioned to be in all markets including the emerging markets. Modern environment friendly technology will be used to develop safe products that are not counterproductive to the wellbeing of the end consumer. The needy people will be served with effective solutions and the new mission passionately suggests sustainable prosperity while engaging creative and intelligent people building profitable shareholder returns thru the whole process. SWOT Analysis External opportunities: O1 – The recent agreement with Schering-Plough opens mo re avenues for potential growth in the fields of respiratory and infectious disease herapeutic segments. (1) O2 – Possible Cost savings of $3. 5 Billon from internal restructuring efforts beyond 2011. (1) O3 – There is a lot of potential for growth in the Diabetes and Oncology markets and Merck has made its entry into this market thru the product Januvia. O4 – Merck can add core strength to its portfolio by expanding research and innovation in the biological markets thru partners, acquisitions and joint ventures. O5 – Rapidly expanding market share in emerging markets proves to be a high potential opportunity for Merck.Emerging Markets in the Pharma Industry will take 50% Growth Credit by 2013. (2) O6- Increased opportunity for new Generic Drug products. Healthcare reform suggests cost savings and insurance industries emphasize usage of generic drugs and the expiring patents on a lot of drugs opens up opportunity for Merck to pioneer the generic drug mark et leveraging its world-class research capabilities. The total market share of the patents that will expire over 2010-2015 is 17% with a market share of $142billion. (17) O7- Pfizer’s animal health business returned a profit of $2. billion which is second to Merck and with the cancelled joint venture of Merck and Sanofi-Aventis, Merck should further pursue their concept with Novartis who are No. 5 in animal health business. This will strengthen their No. 1 position in the light of Pfizer's growing sales and the merger between J;amp;J and Eli Lilly Co in this segment. (3) External Threats: T1 – At least five of the patents are expiring in the next two years and competition is ready to introduce generic products backed by healthcare reform and this can pose a serious threat to Merck’s products and profitability.T2 – The consumer is not the one that usually makes the choice of using a particular drug. Mostly, drugs are prescribed by physicians, who sometimes lack the necessary information about relative prices. (4) T3 – The recent housing market problem, the oil prices problem and the global recession has a cascading effect on the job market and many people are unemployed losing their health insurance and forced to not being able to use medical or pharmaceutical products.If there is no sales in the pharmaceutical products, Merck can suffer financial losses and reduced returns to shareholders. T4 – The HealthCare Reform enacted in 2010 caused unanticipated losses for Merck and the effects of this Act will continue into future. These new provisions will decrease revenue and increase costs. (5) * 2010 – Costs incurred due to increased Medicaid rebates. With respect to the effect of the law on the pharmaceutical industry, the law increased the mandated Medicaid rebate from 15. 1% to 23. 1%. 2011 – An annual health care reform fee on all branded prescription drug manufacturers and importers and the requirement th at drug manufacturers pay a 50% discount on Medicare Part D utilization incurred by beneficiaries when they are in the Medicare Part D coverage also known as the ‘Donut hole’.T5 – Although not included in the health care reform law, Congress has also considered, and may consider again, proposals to increase the government’s role in pharmaceutical pricing in the Medicare program. (5) T6 –    Congress may again consider proposals to allow, under certain conditions, the importation of medicines from other countries. 5) T7 – Merck is experiencing delay in manufacturing some of its vaccines and this delay can cause a competitor to launch a product that can be manufactured quickly. Financial and Operating Performance Analysis Close Competitors Pfizer Inc. Eli Lilly and Company Ratio Analysis | 2006| 2007| 2008| 2009| 2010| Margins (% of Sales)| | | | | | Revenue| 100. 00%| 100. 00%| 100. 00%| 100. 00%| 100. 00%| COGS| 26. 50%| 25. 40%| 23. 40%| 3 2. 90%| 40. 00%| Gross Margin| 73. 50%| 74. 60%| 76. 60%| 67. 10%| 60. 00%| SG;amp;A| 36. 10%| 31. 20%| 30. 90%| 31. 10%| 28. 80%| R;amp;D| 21. 10%| 20. 20%| 20. 10%| 21. 30%| 23. 90%|Other| 0. 60%| 1. 40%| 4. 30%| 6. 00%| 2. 10%| Operating Margin| 15. 70%| 21. 90%| 21. 20%| 8. 70%| 5. 20%| Net Int Inc ;amp; Other| 12. 40%| -7. 40%| 20. 50%| 47. 00%| -1. 60%| EBT Margin| 27. 50%| 13. 90%| 41. 10%| 55. 80%| 3. 60%| Profitability| | | | | | Tax Rate| 28. 70%| 2. 80%| 20. 40%| 14. 80%| 40. 60%| Net Margin| 19. 59%| 13. 54%| 32. 74%| 47. 03%| 1. 87%| Asset Turnover| 0. 51| 0. 52| 0. 5| 0. 34| 0. 42| (Average)| | | | | | Return on Assets| 9. 92%| 7. 05%| 16. 34%| 16. 20%| 0. 79%| Financial Leverage (Average)| 2. 54| 2. 66| 2. 52| 1. 9| 1. 95| Return on Equity| 25. 00%| 18. 33%| 42. 27%| 33. 15%| 1. 1%| Growth| | | | | | Revenue Growth| | | | | | Year over Year| 2. 80%| 6. 90%| -1. 40%| 15. 00%| 67. 70%| 3-Year Average| 0. 20%| 1. 80%| 2. 70%| 6. 60%| 23. 90%| 5-Year Average| -13. 90%| -1 4. 10%| 1. 20%| 3. 60%| 15. 90%| 10-Year Average| 1. 30%| 0. 20%| -1. 20%| -1. 80%| 1. 30%| Operating Income| | | | | | Year over Year| -36. 00%| 49. 30%| -4. 50%| -52. 80%| -0. 70%| 3-Year Average| -24. 90%| -7. 20%| -3. 00%| -12. 30%| -23. 50%| 5-Year Average| -18. 30%| -11. 40%| -9. 60%| -18. 50%| -15. 60%| 10-Year Average| -3. 40%| -0. 70%| -2. 30%| -10. 90%| -12. 60%| EPS| | | | | | Year over Year| -3. 30%| -26. 60%| 144. 0%| 55. 20%| -95. 00%| 3-Year Average| -11. 40%| -17. 00%| 20. 10%| 40. 70%| -42. 70%| 5-Year Average| -8. 40%| -13. 90%| 4. 50%| 16. 70%| -33. 20%| 10-Year Average| 2. 60%| -2. 30%| 5. 40%| 8. 70%| -20. 90%| Cash Flow Ratios| | | | | | Operating Cash Flow Growth-YOY| -11. 10%| 3. 50%| -6. 10%| -48. 40%| 219. 00%| Free Cash Flow Growth-YOY| -6. 80%| 3. 50%| -11. 90%| -63. 40%| 373. 40%| Cap Ex as a % of Sales| 4. 30%| 4. 20%| 5. 40%| 5. 30%| 3. 60%| Free Cash Flow/Sales| 25. 56%| 24. 75%| 22. 11%| 7. 04%| 19. 88%| Free Cash Flow/Net Income| 1. 3| 1. 83| 0. 68| 0. 15| 10. 64| Liquidity/Financial Health| | | | | |Current Ratio| 1. 2| 1. 23| 1. 35| 1. 8| 1. 86| Quick Ratio| 0. 95| 0. 97| 0. 65| 1. 03| 1. 25| Financial Leverage| 2. 54| 2. 66| 2. 52| 1. 9| 1. 95| Debt/Equity| 0. 32| 0. 22| 0. 21| 0. 27| 0. 28| Efficiency| | | | | | Days Sales Outstanding| 50. 3| 52. 4| 56. 7| 69. 1| 55. 4| Days Inventory| 104. 2| 108. 5| 136. 1| 209. 2| 138. 1| Payables Period| 29. 4| 33. 3| 40. 6| 57. 8| 45. 1| Cash Conversion Cycle| 125. 1| 127. 6| 152. 3| 220. 5| 148. 4| Receivables Turnover| 7. 3| 7| 6. 4| 5. 3| 6. 6| Inventory Turnover| 3. 5| 3. 4| 2. 7| 1. 7| 2. 6| Fixed Asset Turnover| 1. 6| 1. 9| 2| 1. 8| 2. 6| Asset Turnover| 0. 5| 0. 5| 0. | 0. 3| 0. 4| Reference – (6) Key Industry Ratios Operating Profit margin 2010| MERCK| PFIZER| Eli Lilly and Company | Operating Profit margin| 5. 2| 20. 3| 28. 3| Merck had Operating Profit margin of 5. 2 OPM%. Merck Operating profit margin is low when compared to competitors; this indicates that there is scope for improving the cost structure. Net Profit margin 2010| MERCK| PFIZER| Eli Lilly and Company | Net Profit margin| 1. 87| 12. 18| 21. 97| Merck had a Net Profit margin i. e. , 1. 87 NPM%. Merck NPM is lower than its competitors. A net profit margin indicates that there is scope for improving the capital structure.Huge percentage drop when compared to 2009 (47%). Current Ratio 2010| MERCK| PFIZER| Eli Lilly and Company | Current Ratio| 1. 86| 2. 11| 2. 09| Current Ratio: Merck has Current Ratio of 1. 8, which shows that Merck may meet short-term obligations. Current Ratio 2. 0 is considered good to meet short-term financial obligations. Return on Assets 2010| MERCK| PFIZER| Eli Lilly and Company | Return on Assets| 0. 79| 4. 05| 17. 34| Return on Assets (ROA): Merck has ROA of 0. 79%, which indicates its assets are NOT at optimum their utilization. Debt/Equity Ratio 2010| MERCK| PFIZER| Eli Lilly and Company |Debt/Equity Ratio| 0. 28| 0. 44| 0. 55| Debt/equity ratio (D/E ratio ): Merck had D/E ratio of . 27, which is good. Inventory Turnover Ratio 2010| MERCK| PFIZER| Eli Lilly and Company | Inventory Turnover Ratio| 2. 6| 1. 6| 1. 6| Inventory Turnover Ratio: Merck has a 2. 6 times turnover ratio, which is good when compare to competitors. It also suggests that loss of sales as it will not have sufficient stock in hand. Revenue Growth 2010| MERCK| PFIZER| Eli Lilly and Company | Revenue Growth| 67. 7| 35. 6| 5. 7| Revenue growth: Merck Sales growth rate is 67%, Revenue growth is very good when compared to competitors.New products Isentress and Januvia  sales boosted revenue. Market Share Market share: – Total Pharmacy industry share is $836 billion and Merck has $46 billion, stands one of the largest company in 2010 – 5. 5 % of Global Market. Internal Strengths S1 – Merck maintains strong financial health despite the $8. 5 billion debt needed for the acquisition. Analysts are predicting that the combined company will generate a $12 billion cash flow in 2011 which should help repay the debt quickly. (7) S2 – Majority of the blockbuster products introduced recently showed very strong sales.Especially, Januvia (diabetes), Isentress (HIV), and Gardasil. (7) S3 – Merck has strong earnings when compared to the industry. | Stock| Industry| S;amp;P 500 | Stock's 5Yr Average*| Price/Earnings| 122. 0| 17. 7| 16. 6| 40. 7| Price/Book| 1. 9| 2. 6| 2. 2| 4. 0| Price/Sales| 2. 3| 2. 6| 1. 4| 3. 5| Price/Cash Flow| 9. 8| 10. 1| 8. 5| 19. 9| Dividend Yield %| 4. 5| 3. 4| 1. 7| —| S4 – Merck’s latest acquisition of Schering results in a $6 billion pipeline of drugs with the potential of multiple blockbusters and very few patent losses are expected over the next couple of years.It is predicted that the combination of the two entities should generate $3 billion plus in annual cost savings before 2011. (8) S5 – Global market presence along with production facilities. Merck operates in 120 countries with 31 factories worldwide. (9) Merck follows a unique strategy of integrated markets as below. (10) S6 – Merck is well positioned in some Emerging Markets and is showing robust growth in China and is actively searching for a partner in India. Merck has developed a separate strategy for positioning itself as numero uno in emerging markets. 11) & (12) S7- A vast diversified product portfolio in Medicines, Vaccines, Biologics, Consumer Care and Animal Health. (12) S8 – It has various  patient assistance programs  in U. S. to help the people who are unable to afford the medical treatment in terms of medicine if household income is less than 400% of Federal Poverty Level. (13) S9 – The firm has robust in-house research capabilities that also make it a leader in designing new medical products. Internal Weakness W1 – EPS dropped from $0. 28 from $5. 7 mainly due which reflect a net unfavorable impact resulting from the amortization of purcha se accounting adjustments, in-process research and development (â€Å"IPR&D†) impairment charges, including a charge related to the vorapaxar clinical development program, restructuring and merger-related costs, as well as a legal reserve relating to Vioxx (the â€Å"Vioxx Liability Reserve†) discussed below, partially offset by the gain recognized on AstraZeneca’s exercise of its option to acquire certain assets. (5) W2 – Singulair is Merck’s largest volume selling pharmacy product with a annual sales of $3. billion as of 2010 and this is expiring in Aug 2012. (5) On top of this, FDA announced that a potential link exists between this product and suicidal behavior. (14) W3 – Few of Merck’s late-stage pipeline products did not get approved by FDA. Following drugs did not get FDA approvals anacetrapib for atherosclerosis, cholesterol drug Tredaptive, Rolofylline for heart disease and Telcagepant for migraines. W4 – The firm faced lawsuits on Vioxx product on increased chances of heart attack and Merck Agreement Provides for $4. 85 Billion Vioxx Settlement Payment. 15) W5 – Merck settled a lawsuit with J&J for $500 million over a dispute on two anti-inflammatory records. Merck also looses marketing rights in some areas. (16) W6 – Merck’s Current ratio is 1. 8, has a limited liquidity position as compared to its competitors. W7 – Merck has minimal presence in the Generic Drug Market. External Factor Evaluation Matrix | External Factor Evaluation Matrix (EFE)|   |   |   |   | Opportunities| Weight| Rating| Weighted Score| 1. | O1 – The recent agreement with Schering-Plough opens more avenues for potential growth in the fields of respiratory and infectious disease therapeutic segments | 0. 8| 4| 0. 32| 2. | O2 – Possible Cost savings of $3. 5 Billon from internal restructuring efforts beyond 2011. | 0. 10| 3| 0. 30| 3. | O3 – There is a lot of po tential for growth in the Diabetes and Oncology markets and Merck has made its entry into this market thru the product Januvia | 0. 05| 3| 0. 15| 4. | O4 – Merck can add core strength to its portfolio by expanding research and innovation in the biological markets thru partners, acquisitions and joint ventures| 0. 05| 1| 0. 05| 5. | O5 – Rapidly expanding market share in emerging markets proves to be a high potential opportunity for Merck.Emerging Markets in Pharma Industry to take 50% Growth Credit by 2013 | 0. 10| 3| 0. 30| 6. | O6- Increased opportunity for new Generic Drug products through more focus on quality R&D. Healthcare reform suggests cost savings and insurance industries emphasize usage of generic drugs and the expiring patents on a lot of drugs opens up opportunity for Merck to pioneer the generic drug market leveraging its world-class research capabilities. The total market share of the patents that will expire over 2010-2015 is 17% with a market shar e of $142billion. | 0. 15| 2| 0. 30| 7. | O7- Pfizer’s animal health business returned a profit of $2. billion which is second to Merck and with the cancelled joint venture of Merck and Sanofi-Aventis, Merck should further pursue their concept with Novartis who are No. 5 in animal health business. This will strengthen their No. 1 position in the light of Pfizer's growing sales and the merger between J;amp;J and Eli Lilly Co in this segment| 0. 02| 3| 0. 06| | | | | | | Threats| Weight| Rating| Weighted Score| 1. | T1 – At least five of the patents are expiring in the next two years and competition is ready to introduce generic products backed by healthcare reform and this can pose a serious threat to Merck’s products and profitability| 0. 5| 2| 0. 30| 2. | T2 – The consumer is not the one that usually makes the choice of using a particular drug. Mostly, drugs are prescribed by physicians, who sometimes lack the necessary information about relative prices. | 0. 05| 3| 0. 15| 3. | T3 – The recent housing market problem, the oil prices problem and the global recession has a cascading effect on the job market and many people are unemployed losing their health insurance and forced to not being able to use medical or pharmaceutical products. If there is no sales in the pharmaceutical products, Merck can suffer financial losses and reduced returns to shareholders. 0. 08| 3| 0. 24| 4. | T4 – The HealthCare Reform enacted in 2010 caused unanticipated losses for Merck and the effects of this Act will continue into future. These new provisions will decrease revenue and increase costs. | 0. 08| 2| 0. 16| 5. | T5 – Although not included in the health care reform law, Congress has also considered, and may consider again, proposals to increase the government’s role in pharmaceutical pricing in the Medicare program. | 0. 03| 3| 0. 09| 6. | T6 – Congress may again consider proposals to allow, under certain conditio ns, the importation of medicines from other countries. 0. 03| 3| 0. 09| 7. | T7 – Merck is experiencing delay in manufacturing some of its vaccines and this delay can cause a competitor to launch a product that can be manufactured quickly. | 0. 03| 2| 0. 06|   | TOTALS| 1. 00|   | 2. 57| Competitive Profile Matrix Competitive Profile Matrix (CPM)| | Merck| Pfizer| Eli Lilly and Company | Critical Success Factors| Weight | Rating| Score| Rating| Score| Rating| Score| Global Expansion| 0. 10| 3| 0. 30| 3| 0. 30| 4| 0. 40| Market Penetration| 0. 06| 4| 0. 24| 4| 0. 24| 2| 0. 12| Pipeline| 0. 15| 3| 0. 45| 4| 0. 60| 2| 0. 30| Patents| 0. 8| 4| 0. 72| 3| 0. 54| 2| 0. 36| R;amp;D| 0. 17| 3| 0. 51| 4| 0. 68| 2| 0. 34| Financial Profit| 0. 05| 2| 0. 10| 3| 0. 15| 4| 0. 20| Customer Loyalty| 0. 00| 3| 0. 00| 3| 0. 00| 2| 0. 00| Market Share| 0. 08| 4| 0. 32| 4| 0. 32| 3| 0. 24| Product Quality| 0. 06| 1| 0. 06| 2| 0. 12| 2| 0. 12| Generic Drugs| 0. 15| 2| 0. 30| 3| 0. 45| 2| 0. 30 | Totals| 1. 00|   | 3. 00|   | 3. 40|   | 2. 38| * Global Expansion: Merck is in 121 countries Pfizer is in 150 countries Eli Lily is in 143 countries. * Pipeline: 94 in Pipeline for Pfizer, Lilly has 15 and 57 in Merck Pipeline excluding registration. Patents: Pfizer has 11 basic patent products and Lily has 8 basic patent products and Merck has 29 basic patent products. * Financial Profit : EPS – Lilly has EPS 4. 58 Merck has 0. 28 Pfizer has 1. 02. * Market Share : Merck has $45 billion and Pfizer has $67 and Lilly has $23 billion. * Product quality : Merck has two major lawsuits whereas Pfizer has one and Lilly has one. * Generic Drugs : Pfizer has 59 generic drugs which is more than what Merck has and what Lilly has Merck is still entering into different JVS with SUN and other pharma companies. Internal Factor Evaluation Internal Factor Evaluation Matrix (IFE)|   |   |   |   | Strengths| Weight| Rating| Weighted Score| 1. | S1 – Merck maintains stro ng financial health despite the $8. 5 billion debt needed for the acquisition. Analysts are predicting that the combined company will generate a $12billion cash flow in 2011 which should help repay the debt quickly. | 0. 05| 4| 0. 20| 2. | S2 – Majority of the blockbuster products introduced recently showed very strong sales. Especially, Januvia(diabetes), Isentress(HIV), and Gardasil. | 0. 08| 4| 0. 32| 3. | S3 – Merck has strong earnings when compared to the industry. | 0. 04| 3| 0. 12| 4. S4 Merck’s latest acquisition of Schering results in a $6 billion pipeline of drugs with the potential of multiple blockbusters and very few patent losses are expected over the next couple of years. It is predicted that the combination of the two entities should generate $3 billion plus in annual cost savings before 2011. | 0. 15| 4| 0. 60| 5. | S5 Global market presence along with production facilities. Merck operates in 120 countries with 31 factories worldwide. | 0. 06| 3 | 0. 18| 6. | S6 Merck is well positioned in some Emerging Markets and is showing robust growth in China and is actively searching for a partner in India.Merck has developed a separate strategy for positioning itself as numero uno in emerging markets. | 0. 15| 3| 0. 45| 7. | S7 A vast diversified product portfolio in Medicines, Vaccines, Biologics, Consumer Care and Animal Health. | 0. 05| 3| 0. 15| | | | | | | Weaknesses| Weight| Rating| Weighted Score| 1. | W1 EPS dropped from $0. 28 from $5. 67 mainly due which reflect a net unfavorable impact resulting from the amortization of purchase accounting adjustments| 0. 04| 2| 0. 08| 2. | W2 Singulair is Merck’s largest volume selling pharma product with a annual sales of $3. 2 billion as of 2010 and this is expiring in Aug 2012. 0. 10| 1| 0. 10| 3. | W3 Few of Merck’s late-stage pipeline products did not get approved by FDA. Following drugs did not get FDA approvals anacetrapib for atherosclerosis, cholesterol drug Tredap tive ,Rolofylline for heart disease ,Telcagepant for migraines| 0. 10| 1| 0. 10| 4. | W4 The firm faced lawsuits on Vioxx product on increased chances of heart attack and Merck Agreement Provides for $4. 85 Billion Vioxx Settlement Payment. | 0. 04| 2| 0. 08| 5. | W5 Merck settled a lawsuit with J;amp;J for $500 million over a dispute on two anti-inflammatory records. Merck also looses marketing rights in some areas. 0. 04| 2| 0. 08| 6. | W6 Merck Current ratio is 1. 8, has a limited liquidity position as compared to its competitors. | 0. 05| 2| 0. 10| 7. | W7 Merck has minimal presence in Generic Drug Market. | 0. 05| 1| 0. 05|   | TOTALS| 1. 00|   | 2. 61| Space Matrix Financial Position: * Return on Investment is Average when compare to Industry. * Leverage: Compared to the industry standard, leverage or debt equity ratio of Merck is more industry is whereas Merck is 0. 27. * Liquidity: Current Ratio is around 1. 8. Above 2. 0 is preferred to meeting Short-term obligations. * Working Capital: Working Capital is low. Cash Flow: Cash Flows for 2010 is very good which is around $9 billion. Industrial Position: * Growth Potential: Revenues are up by 67% and successful new product launches. And successful merger with Schering Plough * Financial Stability: After M;amp;A, company financially is in difficult position, but in long-term it will do better. * Ease of Entry into Market: As Merck already exists in multiple markets and different pharma domains, ease of entry into market is considered high for Merck * Resource Utilization: Merck has ROA of 0. 79%, which indicates its assets are NOT at optimum their utilization. Profit Potential: As free cash flows are high, profit potential is more. Competitive Position: * Market Share: Second in global position * Product Quality: Two products have litigations. * Customer Loyalty: Due to Voixx and other products side effects, customer loyalty became average. * Technological know-how: Getting new biotechnology and bio-p harma industry. * Control over Suppliers and Distributors: Merck has control on Suppliers and Distributors. Sustainability Position: * Rate of Inflation: Same as like other products * Technological Changes: Minimal * Price Elasticity of Demand: As more are patent products, the effect will be less. Competitive Pressure: Yes, there is lot of competition with pharma and other generic drug products. * Barriers to Entry into Market: Minimum Barriers. SWOT Matrix SO Strategies: * S5O5O6: Healthcare reform emphasizes a paradigm shift to generic drugs from branded drugs and 17% of the patented drugs are going to expire by 2015 and this is an opportunity of $142 billion and there are not a lot of market players in this segment yet. Merck can take advantage of this upcoming situation and start working on generic drugs in the pipeline to be released in the established and emerging markets.We believe Merck should be able to tap into at least $50billion by this strategy. * S4O4O1: Merck’s merger with Schering results in a $6billion of pipeline of drugs and not many patents are expiring in this set. This strategy will result in $3billion of savings before 2011. Merck should further expand their research and innovation thru joint ventures and innovations in the current, biogenetics and other potential domains and follow a market penetration strategy in current and emerging markets.Merck should further expand their research and innovation thru joint ventures and innovations in the current, biogenerics and other potential domains and follow a market penetration strategy in current and emerging markets. ST Strategies: * S6T4T1: Healthcare reform can cause major losses in the domestic market and many laws of healthcare are not yet in implementation and the result of this will continue thru 2014 and so, Merck should start expanding globally beyond its current footprint and should focus on generic drugs as a majority of the emerging markets prefer inexpensive drugs compared to branded expensive drugs.The savings here are double-edged as we minimize the effect of healthcare reform oriented costs and we expand globally and earn more before competition takes over. The potential savings by this strategy is estimated to be a minimum of $4billion in the next one year considering we have a good presence in many established and emerging markets. * S7T2: Merck should start implementing a pharmacy management program by working closely with physicians and customers to deliver a one-of-a-kind integrated specialty pharmacy in every national segment that is part of Merck's client advisory board.This pharmacy management program specifically targets specialty medications for a number of chronic conditions and helps them better understand their condition, medication side effects, and the importance of adherence. WO Strategies: * W2O6O5W7: Singuliar is a branded product of Merck the patent of which is going to expire in 2012 and Merck should equip itself by penetrating into the generic drugs market that will substitute Singuliar and Merck should rapidly expand in emerging markets and focus on improving in existing markets to position itself better for the post patent expiration loss of sale. W3O4: FDA's denial of products in research and development can setback the product development lifecycle timeline during which competition can catch up and release their own branded or generic drug and so Merck should expand its research and innovation to adopt latest technologies for quicker innovation and also use joint ventures or partners or possible acquisitions to quickly supplement its lacunae in the research areas and thereby position itself for success. WT Strategies: * T1W2: More than six of Merck's patents are expiring in the near term.The additional capacity realized upon the cessation of Singuliar manufacturing should be used for high potential drugs which will face limited competition. The high potential drugs in the pipeline approved by FDA sho uld be made ready for use for the additional capacity. * W3T3: The current recession caused by multiple problems can hit Merck's profitability and the failure of FDA approvals can cause further sunk losses in the research and development area. Merck should look into outsourcing research and development to places where it is inexpensive for research.Grand Strategy Matrix The extensive analysis of Merck suggests the first quadrant of the Grand Strategy Matrix. Merck is in a good long term strategy and should continue to pursue its strategic plans and the recommended strategies. Recommended Strategies Recommended strategy No. 1: Healthcare reform emphasizes a paradigm shift to generic drugs from branded drugs in an effort to save money for the consumers and to eliminate undue profits for the healthcare or pharma industries. 7% of the patented drugs are going to expire by 2015 and this is an opportunity of $142 billion and there are not a lot of market players in this segment yet. Merck can take advantage of this upcoming situation and start working on generic drugs in the pipeline to be released in the established and emerging markets. We believe Merck should be able to tap into at least $50billion by this strategy over the next five years with an immediate return of $15billion in the upcoming fiscal year.More research and development can be leveraged by outsourcing research and development into areas where it’s more productive for the investment. A more detailed vision of this strategy in monetary terms is presented in the next section to give the audience a perspective of how this strategy is beneficial in making Merck the number one in the industry with sustainable prosperity laying the foundation to diversify into pharmacy management program in light of the healthcare reform. Recommended strategy No. 2:Merck should start implementing a pharmacy management program by working closely with physicians and customers to deliver a one-of-a-kind integrated spe cialty pharmacy in every national segment that is part of Merck's client advisory board. This pharmacy management program specifically targets specialty medications for a number of chronic conditions and helps them better understand their condition, medication side effects, and the importance of adherence. More research and development is suggested in areas that Merck can improve upon and the excess capacity that will be obtained after Singular should be used for pipeline products.This will position Merck as a differentiator in not just health but the health and wellness industry and will form a close nexus with physicians and customers while pursuing research in the most needed areas to improve life and wellbeing as visualized in the revised mission. Projected Financial Statements Projected Income Statement| | | | | 2010| 2011| | Revenue| 45,987. 00| 62832| Around $17 bln increase due to new strategies| COGS| 18,396. 00| 21991. 2| 35% of revenue| Gross Profit| 27,591. 00| 40840. 8| | | | | | Operating Expenses $Mil| | | | SG&A| 13,245. 00| 15708| 25% of sales | R&D| 10,991. 0| 13991| allocated $3 billion more| Other| 985| 985| | Pharmacy Management| | 200| | New Market Development expense| | 300| | Operating Income| 2,370. 00| 9656. 8| | Other Income and Expense $Mil| | | | Net Int Inc & Other| -717| -717| | Earnings Before Taxes| 1,653. 00| 8939. 8| | Income Taxes| 671| 3575. 92| 40% tax| Earnings After Taxes| 982| 5543. 88| | Acctg Changes| —| | | Disc Operations| —| | | Ext Items| -123| -123| | Net Income| 859| 5420. 88| | Diluted EPS, Cont Ops$| 0. 28| 0. 37| | Diluted EPS$| 0. 28| 0. 37| | Shares| 3,120. 00| 3208| | | | | | Project Balance Statement| | | |Assets $Mil| | | | | 2010| 2011| | Cash and Equiv| 10,900. 00| 11500| | Short-Term Investments| 1,301. 00| 1320| | Accts Rec| 7,344. 00| 11016| 50% increase| Inventory| 5,868. 00| 7335| 25% increase| Other Current Assets| 3,651. 00| 4250| | Total Current Assets| 29,064. 00| 354 21| | Net PP&E| 17,082. 00| 19555| | Intangibles| 51,834. 00| 52544| | Other Long-Term Assets| 7,801. 00| 8022| | Total Assets| 105,781. 00| 150963| | | | | | Liabilities and Stockholders' Equity $Mil| | | | | 2010| 2011| | Accts Payable| 2,308. 00| 2828| | Short-Term Debt| 2,400. 00| 2605| | Taxes Payable| 1,243. 0| 1300| | Accrued Liabilities| 8,514. 00| 8914| | Other Short-Term Liabilities| 1,176. 00| 1220| | Total Current Liabilities| 15,641. 00| 16867| | Long-Term Debt| 15,482. 00| 18282| | Other Long-Term Liabilities| 20,282. 00| 30455| | Total Liabilities| 51,405. 00| 55604| | Total Equity| 54,376. 00| 85359| | Total Liabilities ;amp; Equity| 105,781. 00| 150963| | Projected Ratios | 2010| 2011| Debt/Equity Ratio| 0. 28| 0. 65| Return on Assets| 0. 79| 3. 59| Net Profit margin| 1. 87| 8. 6| EPS| . 28| 1. 49| Company worth Analysis Net Worth Analysis |   | |   | Stockholders Equity| $66,754,000,000 |Net Income x 5| $4,295,000,000 | (Share Price/EPS) x Net Income| $104, 429,857,143 | Number of Shares Outstanding x Share Price| $104,948,066,926 | Method Average| $70,106,731,017 | Annual Objectives: * A projected increase in sales of $18bn is to be expected for 2011 and reduction of Singuliar sales will be $3bn resulting in $15bn. * An additional expense of $3bn for research and development is assumed for 2011 as part of recommendation 2. * A new category of expenses called â€Å"Pharmacy management expenses† will appear in statement for the amortization expenses of the start up of pharmacy management. A spike in interest of $200mn should be planned for due to the loan required for pharmacy management. * The pharmacy management program is expected to yield $2bn in profits in the first year. * New market development expenses should be planned for $300mn. * Merck should plan on generating equity to the tune of $30bn in the year 2011 to meet the expenses related to increased sales. Strategic Review and Evaluation Procedures: * At the end of the y ear, Merck should compare the stated objectives with the actual data.A re-evaluation of IFE and EFE should be implemented and should be checked for variance against the current IFE and EFE. * If no major variance is observed, the same strategies can be continued thru the following year. At the same time, if the result of these strategies position Merck in a better place, few more aggressive quadrant strategies should be evaluated and considered at that moment. * In the case of a situation where a wide variance is observed from the planned strategies, corrective actions are recommended after careful evaluation of factors from all relevant dimensions to check the main cause/s of the variance.A revised vision, mission and objectives may be needed at that moment in light of the new changes in external and internal factors. * We would also like to recommend usage of a balanced scorecard to evaluate the firm from multiple dimensions and ensure the overall progress of the firm follows the trajectory. * Key performance indicators should be evaluated from time to time internally against the plans or annual objectives and with industry standards for averages to identify any needed changes to the strategy.

Human Systems Essay Example | Topics and Well Written Essays - 1000 words

Human Systems - Essay Example Development of writing skills is an asset that can be used in my future undertakings. While a writing skill can be useful in the rank-and-file positions, it can be more helpful for one holding a position of leadership. I agree with the Lin Grensing 1988 report declaring that â€Å"one of the most important to productivity† is a writing skill (Hansen & Hansen, 2008, para. 5). And even as early as 1991, the U.S. Labor Department had already said that majority of jobs in the coming years would indeed need writing skills (Hansen & Hansen, 2008) and that includes the computer and information technology sector. Writing skill is necessary in many line of work. In some areas, it may even contribute to success in one's career. Its importance cannot be simply ignored because it is a mode by which we communicate with others and exchange ideas. Whether a person is in computer programming or software production, exchange of ideas with colleagues is indispensable. My discipline is primarily concerned with computers and the people using them. At first glance, it may seem that there is no need for someone involved in my discipline to have any skill in writing. As long as I can speak with the people using the computers, then that would be enough. ... There is a need to file them in the folder for archiving or reference at a future time. Some documents and reports have to be submitted to my immediate supervisor and the higher officers of the organisation. Other written documents are intended to be read by my peers. These written forms should be made in a formal manner and to do it, I must possess that skill in writing that conforms to a certain writing style. Moreover, there is a specific format in writing formal business documents. The document must also convey the message clearly. Corporate and business correspondences are intended to transfer critical or important information. And whatever message intended by the sender to be disseminated to the rest of the members of the organization, it must be understood as what the sender intended it to be. A faulty written document can relay a wrong impression or an erroneous interpretation. It can have a disastrous effect upon the business or the organisation as a whole. A writing skill t hen, is crucial to the internal operation of any business or company. In the same manner, when holding a higher position such as that of a manager, a skill in writing is also necessary. The manager has to write reports, letters, and messages for subordinates (Stiller, 2010). Such documents must be easily understandable by the intended recipient, otherwise, it will be consume unnecessary time for the readers to figure out what the author is trying to convey or what instructions are being relayed. If it is a safety instruction and has been misunderstood, an accident or injury can result. An example in my discipline that concerns computer and people working with it can be exemplified clearly in this simple scenario. There are several computer units

An Examination of Intertextuality Between Alice Munros Simons Luck and Essay

An Examination of Intertextuality Between Alice Munros Simons Luck and Margaret Atwoods Happy Endings - Essay Example Whether or not the average reader is familiar with the particulars of the hypothesis, one cannot avoid several decades of literature and culture influenced by these ideas, as they range from the daydreams of Thurber's The Secret Life of Walter Mitty to the fantastic worlds of C. S. Lewis's Narnia books. The two stories examined in this paper, Alice Munro's "Simon's Luck" and Margaret Atwood's "Happy Endings," couple the form of multiple realities with the human psychology of traditional literature. Reader's need only the latent immersion of the involved concepts that permeate the today's world; their inner empathy and the authors' skill will maintain one's attention. Only through closer examination can the levels of intertextuality begin to be distinguished, compared, and analyzed. Munro's story has already existed in a different reality, i.e. it was originally published in 1978 under the title "Emily," which perhaps was the narrator's name before she blossomed into this incarnation as Rose. The reason for the name change will be addressed momentarily. Rose's first instance of confusing reality happens when she is accosted by the student at the party. While she registers that his name is David and that he is a former student, she recalls nothing else, and instead idly projects a history onto him, "He had probably been brought up in a gentle home, where people talked about answering Nature's call and blessed each other for sneezing." When Simon later fails to come to the house, Rose realizes that "Preparations court disaster," in that she had been preparing for one future that did not happen. To console herself, she then imagines alternate futures in which she takes action, either by calling him or writing him a note, or alternately, where he has taken action, by going traveling or having gotten married. She lives through all of these realities through the course of the weekend. Rose has lived through a number of different realities, between teaching and acting, but her relationships patterns seem to end with her fleeing regardless of what the situation was. AS she flees away from Simon, she imagines a number of possibilities for what he is doing, perhaps pulling up to her house. She imagines how the retionship would have only become more akward with time. To escape this cycle of depression, she has extended her excuse to the university, saying that she has run into a job opportunity a future she has accurately predicted for once. She lands an acting role and moves out to British Columbia. Months later, she meets a mutual acquaintance or hers and Simon's, at which point she learns that Simon has died, apparently from an illness that he had for some time. While the title of the story initially seems to relate to the anecdote Simon tells of escaping during World War II, it actually relates to his ultimate fate. For all of the possible futures that Rose had imagined for him, of all the endings she has ever experienced for relationships, his death was tailor made as the only possibility to truly exit her life. He will always be unique to her for that, if no other reason. And as for the

Tourism Marketing Research Proposal Example | Topics and Well Written Essays - 1000 words

Tourism Marketing - Research Proposal Example The research is thus undertaken to understand the different dimensions of tourism marketing and ho this elates to marketing of tourist spots and what are the approaches involved in marketing such tourist places or locations. The concepts of brands and creativity or innovation are also highlighted in the discussion. There are several research questions in this study and based on these research questions, some of the research articles and analysis published in journals will be examined and a comparison of the research approach with the already published research viewpoints will be sought. The main research question is whether or how the approach to tourism marketing and management should change or differ in case of architectural landmark as against tourism marketing of regular destination or location. Are there special approaches to promoting a particular tourist spot and how is it possible to differentiate between destination and location and tourist sites such as architectural landmarks in tourism marketing and management Considering the approaches to tourism marketing in promoting destinations and tourist or architectural sites as brands, several research studies and published papers could be used to substantiate the background of the study. The research study is to be focused on destination marketing and tourist destination as brands as it is important to develop branding approaches for any successful marketing venture. As Kerr (2006) has indicated, destination marketing organizations with government support have been responsible for promoting certain locations and tourist spots and there is suggestion to review such responsibilities and approaches. However there are downsides to destination marketing as this sort of marketing is solely tourism focused and tend to overlook stakeholder prospects or investments in these locations so may not be completely productive for the overall development of a location. Brand management of any particular location deals with the holistic approach of actually changing the potential of a location from an ordinary location to a tourist friendly destination. However according to Kerr there is a need to reform destination marketing practices as it is important to address brand management of locations. Kerr draws out a distinction between destination brand and location brand with the potentially relevant research areas as in the study of brand management of locations. In another related paper, Perivoliotis and Margaret (2007) studied local tourist producers and businesses involved in artifacts and textiles. The paper focuses on how tourism marketing could bank in on the strengths of the local markets and cultural heritage of any product and also brings out the importance of creativity, innovation, productivity, education in any tourism marketing and management initiative. New technology is primarily important in tourism marketing as it could be used to select participating tourist producers and marketers or managers and basic design education and computer training as also basic management and marketing